563 A case series of neoadjuvant ipilimumab and nivolumab in 2 patients with locoregional mucosal melanoma

Antzeko izenburuak

• Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma
  nork: Mahir Hasan, et al.
  Argitaratua: (2026-05-01)
• Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab
  nork: Oskar Krueger, et al.
  Argitaratua: (2024-05-01)
• A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab
  nork: Baylor Akhavan, et al.
  Argitaratua: (2026-01-01)
• Long-term response of vulvar mucosal melanoma treated with neoadjuvant nivolumab
  nork: Margaux Dubus, MD, et al.
  Argitaratua: (2023-08-01)
• Adjuvant and neoadjuvant immunotherapy for acral and mucosal melanoma
  nork: Takaya Komori, et al.
  Argitaratua: (2025-01-01)